{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:10:36Z","timestamp":1784131836674,"version":"3.55.0"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10650-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:23:27Z","timestamp":1784125407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation osteosarcoma models for precision medicine"],"prefix":"10.1038","volume":"9","author":[{"given":"Mohamed","family":"Saqawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-6042","authenticated-orcid":false,"given":"Miguel Vieira","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Villette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3341-0424","authenticated-orcid":false,"given":"Lorenzo","family":"Apolloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Panseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Silva-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Seabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-0868","authenticated-orcid":false,"given":"Nuno","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Staumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"Geris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-6245","authenticated-orcid":false,"given":"Carlos","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-8554","authenticated-orcid":false,"given":"Monica","family":"Montesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-9014","authenticated-orcid":false,"given":"Tatiana M.","family":"Fernandes Patr\u00edcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"10650_CR1","doi-asserted-by":"crossref","unstructured":"Liang, H., Cui, M., Tu, J. & Chen, X. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies. Front. Cell Dev. Biol. 12, 1394339 (2024).","DOI":"10.3389\/fcell.2024.1394339"},{"key":"10650_CR2","doi-asserted-by":"crossref","unstructured":"Mersfelder, R. B. et al. Chemotherapy\u2013surgery interval effects on tumor necrosis and outcome in children and young adults with osteosarcoma. Pediatr. Blood Cancer 72, e31466 (2025).","DOI":"10.1002\/pbc.31466"},{"key":"10650_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/1878-0261.13526","volume":"18","author":"W Liu","year":"2024","unstructured":"Liu, W. et al. The correlation between clinical outcomes and genomic analysis with high-risk factors for the progression of osteosarcoma. Mol. Oncol. 18, 939\u2013955 (2024).","journal-title":"Mol. Oncol."},{"key":"10650_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13720-0","volume":"25","author":"H Hosseini","year":"2025","unstructured":"Hosseini, H., Heydari, S., Hushmandi, K., Daneshi, S. & Raesi, R. Bone tumors: a systematic review of prevalence, risk determinants, and survival patterns. BMC Cancer 25, 321 (2025).","journal-title":"BMC Cancer"},{"key":"10650_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28493","volume":"10","author":"Y Yao","year":"2024","unstructured":"Yao, Y., Wang, D., Zheng, L., Zhao, J. & Tan, M. Advances in prognostic models for osteosarcoma risk. Heliyon 10, e28493 (2024).","journal-title":"Heliyon"},{"key":"10650_CR6","unstructured":"Prater, S. & McKeon, B. Osteosarcoma(Archived). StatPearls https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549868\/ (2023)."},{"key":"10650_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird, H. C. et al. Osteosarcoma. Nat. Rev. Dis. Primers 8, 77 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10650_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s44164-022-00008-x","volume":"1","author":"J Rodrigues","year":"2022","unstructured":"Rodrigues, J., Sarmento, B. & Pereira, C. L. Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.  Vitr. Models 1, 5\u201327 (2022).","journal-title":"Vitr. Models"},{"key":"10650_CR9","doi-asserted-by":"crossref","unstructured":"Du, X. et al. Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities. Front. Oncol. 13, 1117867 (2023).","DOI":"10.3389\/fonc.2023.1117867"},{"key":"10650_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s13402-021-00598-w","volume":"44","author":"Q Huang","year":"2021","unstructured":"Huang, Q. et al. The role of tumor-associated macrophages in osteosarcoma progression\u2014therapeutic implications. Cell. Oncol. 44, 525\u2013539 (2021).","journal-title":"Cell. Oncol."},{"key":"10650_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/jcm10061182","volume":"10","author":"R Rathore","year":"2021","unstructured":"Rathore, R. & Van Tine, B. A. Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies. J. Clin. Med. 10, 1182 (2021).","journal-title":"J. Clin. Med."},{"key":"10650_CR12","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1074\/jbc.RA118.005778","volume":"294","author":"R Shekhar","year":"2019","unstructured":"Shekhar, R. et al. The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression. J. Biol. Chem. 294, 4381\u20134400 (2019).","journal-title":"J. Biol. Chem."},{"key":"10650_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/CMAR.S495169","volume":"17","author":"H Jiang","year":"2025","unstructured":"Jiang, H. Prostate cancer bone metastasis: molecular mechanisms of tumor and bone microenvironment. Cancer Manag. Res. 17, 219\u2013237 (2025).","journal-title":"Cancer Manag. Res."},{"key":"10650_CR14","doi-asserted-by":"crossref","unstructured":"Corre, I., Verrecchia, F., Crenn, V., Redini, F. & Trichet, V. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells. 9, 976 (2020).","DOI":"10.3390\/cells9040976"},{"key":"10650_CR15","doi-asserted-by":"crossref","unstructured":"Makielski, K. M. et al. Risk factors for development of Canine and Human Osteosarcoma: a comparative review. Vet Sci. 6, 48 (2019).","DOI":"10.3390\/vetsci6020048"},{"key":"10650_CR16","doi-asserted-by":"crossref","unstructured":"Lietz, C. E. et al. Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma. Commun. Biol. 5, 213 (2022).","DOI":"10.1038\/s42003-022-03117-1"},{"key":"10650_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill, J. & Gorlick, R. Advancing therapy for osteosarcoma. Nat. Rev. Clin. Oncol. 18, 609\u2013624 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10650_CR18","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.3390\/cancers14143503","volume":"14","author":"B Moukengue","year":"2022","unstructured":"Moukengue, B. et al. Origin and therapies of osteosarcoma. Cancers 14, 3503 (2022).","journal-title":"Cancers"},{"key":"10650_CR19","first-page":"1099","volume":"19","author":"JWV de Azevedo","year":"2019","unstructured":"de Azevedo, J. W. V. et al. Biology and pathogenesis of human osteosarcoma. Oncol. Lett. 19, 1099 (2019).","journal-title":"Oncol. Lett."},{"key":"10650_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bone.2014.02.003","volume":"62","author":"AJ Mutsaers","year":"2014","unstructured":"Mutsaers, A. J. & Walkley, C. R. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone 62, 56\u201363 (2014).","journal-title":"Bone"},{"key":"10650_CR21","doi-asserted-by":"publisher","unstructured":"Zheng, Y., Wang, G., Chen, R., Hua, Y. & Cai, Z. Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications. https:\/\/doi.org\/10.1186\/s13287-018-0780-x (2018).","DOI":"10.1186\/s13287-018-0780-x"},{"key":"10650_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/sicotj\/2017028","volume":"4","author":"A Misaghi","year":"2018","unstructured":"Misaghi, A., Goldin, A., Awad, M. & Kulidjian, A. A. Osteosarcoma: a comprehensive review. Sicot. J. 4, 12 (2018).","journal-title":"Sicot. J."},{"key":"10650_CR23","doi-asserted-by":"crossref","unstructured":"McGee, L. E. et al. The tumor microenvironment of metastatic osteosarcoma in the human and canine lung. Commun. Biol. 8, 756 (2025).","DOI":"10.1038\/s42003-025-07992-2"},{"key":"10650_CR24","doi-asserted-by":"crossref","unstructured":"Das, S. et al. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. Commun. Biol. 4, 1178 (2021).","DOI":"10.1038\/s42003-021-02683-0"},{"key":"10650_CR25","doi-asserted-by":"crossref","unstructured":"Sheng, G., Gao, Y., Yang, Y. & Wu, H. Osteosarcoma and metastasis. Front. Oncol. 11, 780264 (2021).","DOI":"10.3389\/fonc.2021.780264"},{"key":"10650_CR26","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cells10112944","volume":"10","author":"J Ban","year":"2021","unstructured":"Ban, J., Fock, V., Aryee, D. N. T. & Kovar, H. Mechanisms, diagnosis and treatment of bone metastases. Cells 10, 2944 (2021).","journal-title":"Cells"},{"key":"10650_CR27","doi-asserted-by":"crossref","unstructured":"Cheng, S., Wang, H., Kang, X. & Zhang, H. Immunotherapy innovations in the fight against osteosarcoma: emerging strategies and promising progress. Pharmaceutics. 16, 251 (2024).","DOI":"10.3390\/pharmaceutics16020251"},{"key":"10650_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jor.24227","volume":"37","author":"F Tang","year":"2019","unstructured":"Tang, F. et al. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. J. Orthop. Res. 37, 789\u2013798 (2019).","journal-title":"J. Orthop. Res."},{"key":"10650_CR29","first-page":"6228","volume":"16","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Progress in the chemotherapeutic treatment of osteosarcoma (Review). Oncol. Lett. 16, 6228\u20136237 (2018).","journal-title":"Oncol. Lett."},{"key":"10650_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu, S. & Yao, X. Advances on immunotherapy for osteosarcoma. Mol. Cancer 23, 192 (2024).","journal-title":"Mol. Cancer"},{"key":"10650_CR31","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","volume":"6","author":"L Mirabello","year":"2020","unstructured":"Mirabello, L. et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 6, 724\u2013734 (2020).","journal-title":"JAMA Oncol."},{"key":"10650_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01749-1","volume":"39","author":"B Demir Cetinkaya","year":"2022","unstructured":"Demir Cetinkaya, B. & Biray Avci, C. Molecular perspective on targeted therapy in breast cancer: a review of current status. Med. Oncol. 39, 149 (2022).","journal-title":"Med. Oncol."},{"key":"10650_CR33","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1021\/acsapm.1c00297","volume":"3","author":"G Demirci","year":"2021","unstructured":"Demirci, G. et al. (Bis)phosphonic acid-functionalized poly(ethyleneimine)-poly(amido amine)s for selective in vitro transfection of osteosarcoma cells. ACS Appl. Polym. Mater. 3, 3776\u20133787 (2021).","journal-title":"ACS Appl. Polym. Mater."},{"key":"10650_CR34","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jgm.308","volume":"4","author":"MA Witlox","year":"2002","unstructured":"Witlox, M. A. et al. Epidermal growth factor receptor targeting enhances adenoviral vector- based suicide gene therapy of osteosarcoma. J. Gene Med. 4, 510\u2013516 (2002).","journal-title":"J. Gene Med."},{"key":"10650_CR35","first-page":"705","volume":"13","author":"A Ketola","year":"2004","unstructured":"Ketola, A., M\u00e4\u00e4tt\u00e4, A. M., Pasanen, T., Tulim\u00e4ki, K. & Wahlfors, J. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase\/ganciclovir gene therapy. Int. J. Mol. Med. 13, 705\u2013710 (2004).","journal-title":"Int. J. Mol. Med."},{"key":"10650_CR36","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/labinvest.3700444","volume":"86","author":"VV Ternovoi","year":"2006","unstructured":"Ternovoi, V. V., Curiel, D. T., Smith, B. F. & Siegel, G. P. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab. Investig. 86, 748\u2013766 (2006).","journal-title":"Lab. Investig."},{"key":"10650_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-024-01641-7","volume":"17","author":"M Pezzella","year":"2024","unstructured":"Pezzella, M. et al. Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. J. Hematol. Oncol. 17, 127 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"10650_CR38","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41556-022-00969-x","volume":"24","author":"Z Li","year":"2022","unstructured":"Li, Z., Seehawer, M. & Polyak, K. Untangling the web of intratumour heterogeneity. Nat. Cell Biol. 24, 1192\u20131201 (2022).","journal-title":"Nat. Cell Biol."},{"key":"10650_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-025-03734-w","volume":"25","author":"YC Fu","year":"2025","unstructured":"Fu, Y. C., Liang, S. B., Luo, M. & Wang, X. P. Intratumoral heterogeneity and drug resistance in cancer. Cancer Cell Int. 25, 1\u201318 (2025).","journal-title":"Cancer Cell Int."},{"key":"10650_CR40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212\u2013224 (2021).","journal-title":"Nat. Med."},{"key":"10650_CR41","doi-asserted-by":"publisher","first-page":"1121020","DOI":"10.3389\/fmed.2023.1121020","volume":"10","author":"DA Osorio-Rodr\u00edguez","year":"2023","unstructured":"Osorio-Rodr\u00edguez, D. A., Camacho, B. A. & Ram\u00edrez-Segura, C. Anti-ROR1 CAR-T cells: Architecture and performance. Front. Med. 10, 1121020 (2023).","journal-title":"Front. Med."},{"key":"10650_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41379-018-0109-4","volume":"32","author":"DL Rimm","year":"2019","unstructured":"Rimm, D. L. et al. An international multicenter study to evaluate the reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod. Pathol. 32, 59\u201369 (2019).","journal-title":"Mod. Pathol."},{"key":"10650_CR43","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2) - Specific chimeric antigen receptor - Modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688\u20131696 (2015).","journal-title":"J. Clin. Oncol."},{"key":"10650_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cjp2.191","volume":"7","author":"B Ameline","year":"2020","unstructured":"Ameline, B. et al. Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? J. Pathol. Clin. Res. 7, 165 (2020).","journal-title":"J. Pathol. Clin. Res."},{"key":"10650_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-024-01811-7","volume":"22","author":"G Giordano","year":"2024","unstructured":"Giordano, G., Tucciarello, C., Merlini, A., Cutrupi, S. & Pignochino, Y. Targeting the EphA2 pathway: could it be the way for bone sarcomas? Cell Commun. Signal. 22, 1\u201322 (2024).","journal-title":"Cell Commun. Signal."},{"key":"10650_CR46","first-page":"3248","volume":"10","author":"D Cao","year":"2020","unstructured":"Cao, D. et al. Blockade of IGF\/IGF-1R signaling axis with soluble IGF-1R mutants suppresses the cell proliferation and tumor growth of human osteosarcoma. Am. J. Cancer Res. 10, 3248 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"10650_CR47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha, B., Inal, C. & Owonikoko, T. K. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol. 10, 1000 (2020).","journal-title":"Front. Oncol."},{"key":"10650_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","volume":"172","author":"P Hingorani","year":"2022","unstructured":"Hingorani, P. et al. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: a report from the Children\u2019s Oncology Group. Eur. J. Cancer 172, 264\u2013275 (2022).","journal-title":"Eur. J. Cancer"},{"key":"10650_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 1\u201354 (2023).","journal-title":"Mol. Cancer"},{"key":"10650_CR50","doi-asserted-by":"publisher","first-page":"e70689","DOI":"10.1371\/journal.pone.0070689","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One 8, e70689 (2013).","journal-title":"PLoS One"},{"key":"10650_CR51","doi-asserted-by":"publisher","first-page":"152420","DOI":"10.1016\/j.prp.2019.04.012","volume":"215","author":"L He","year":"2019","unstructured":"He, L. & Li, Z. B7-H3 and its role in bone cancers. Pathol. Res. Pract. 215, 152420 (2019).","journal-title":"Pathol. Res. Pract."},{"key":"10650_CR52","unstructured":"Jordyn, S. FDA Grants B7-H3\u2013Targeted ADC Breakthrough Status in Osteosarcoma. https:\/\/www.targetedonc.com\/view\/fda-grants-b7-h3-targeted-adc-breakthrough-status-in-osteosarcoma."},{"key":"10650_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-10229-8","volume":"22","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer 22, 1\u201312 (2022).","journal-title":"BMC Cancer"},{"key":"10650_CR54","doi-asserted-by":"publisher","first-page":"1290762","DOI":"10.3389\/fimmu.2023.1290762","volume":"14","author":"S Li","year":"2023","unstructured":"Li, S., Zhang, H. & Shang, G. Current status and future challenges of CAR-T cell therapy for osteosarcoma. Front. Immunol. 14, 1290762 (2023).","journal-title":"Front. Immunol."},{"key":"10650_CR55","first-page":"1","volume":"38","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J. Exp. Clin. Cancer Res. 38, 1\u201311 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10650_CR56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-3-319-04843-7_15","volume":"804","author":"VO Lewis","year":"2014","unstructured":"Lewis, V. O. IL-11R\u03b1: a novel target for the treatment of osteosarcoma. Adv. Exp. Med. Biol. 804, 285\u2013289 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"10650_CR57","unstructured":"Mepact | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mepact."},{"key":"10650_CR58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/14656566.2011.543129","volume":"12","author":"K Ando","year":"2011","unstructured":"Ando, K., Mori, K., Corradini, N., Redini, F. & Heymann, D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin. Pharmacother. 12, 285\u2013292 (2011).","journal-title":"Expert Opin. Pharmacother."},{"key":"10650_CR59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/TCRM.S5688","volume":"6","author":"L Kager","year":"2010","unstructured":"Kager, L., P\u00f6tschger, U. & Bielack, S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther. Clin. Risk Manag. 6, 279\u2013286 (2010).","journal-title":"Ther. Clin. Risk Manag."},{"key":"10650_CR60","doi-asserted-by":"crossref","unstructured":"M\u00fadry, P. et al. Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy\u2014Observational prospective single institution analysis. J. Bone Oncol. 28, 100362 (2021).","DOI":"10.1016\/j.jbo.2021.100362"},{"key":"10650_CR61","doi-asserted-by":"crossref","unstructured":"Demiya, K. et al. p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death. Mol. Ther. Oncol. 32, 200845 (2024).","DOI":"10.1016\/j.omton.2024.200845"},{"key":"10650_CR62","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"10650_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-030-43032-0_8","volume":"1257","author":"DR Reed","year":"2020","unstructured":"Reed, D. R., Hingorani, P. & Anderson, P. M. Relapsed osteosarcoma trial concepts to match the complexity of the disease. Adv. Exp. Med. Biol. 1257, 85\u201394 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"10650_CR64","doi-asserted-by":"crossref","unstructured":"Joshi, S. & Durden, D. L. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. J. Oncol. 2019, 5245034 (2019).","DOI":"10.1155\/2019\/5245034"},{"key":"10650_CR65","doi-asserted-by":"crossref","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 36, 471\u2013482 (2019).","DOI":"10.1016\/j.ccell.2019.09.006"},{"key":"10650_CR66","doi-asserted-by":"crossref","unstructured":"Tan, L. et al. Advances of osteosarcoma models for drug discovery and precision medicine. Biomolecules 13, 1362 (2023).","DOI":"10.3390\/biom13091362"},{"key":"10650_CR67","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1089\/ten.teb.2020.0254","volume":"27","author":"T Chow","year":"2021","unstructured":"Chow, T. et al. Creating in vitro three-dimensional tumor models: a guide for the biofabrication of a primary osteosarcoma model. Tissue Eng. Part B Rev. 27, 514\u2013529 (2021).","journal-title":"Tissue Eng. Part B Rev."},{"key":"10650_CR68","doi-asserted-by":"publisher","first-page":"1175503","DOI":"10.3389\/fimmu.2023.1175503","volume":"14","author":"N Manduca","year":"2023","unstructured":"Manduca, N., Maccafeo, E., De Maria, R., Sistigu, A. & Musella, M. 3D cancer models: one step closer to in vitro human studies. Front. Immunol. 14, 1175503 (2023).","journal-title":"Front. Immunol."},{"key":"10650_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fmolb.2020.00033","volume":"7","author":"C Jensen","year":"2020","unstructured":"Jensen, C. & Teng, Y. Is it time to start transitioning from 2D to 3D cell culture? Front. Mol. Biosci. 7, 33 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"10650_CR70","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","volume":"74","author":"JL Wilding","year":"2014","unstructured":"Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res. 74, 2377\u20132384 (2014).","journal-title":"Cancer Res."},{"key":"10650_CR71","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1158\/0008-5472.CAN-06-3674","volume":"67","author":"J Greshock","year":"2007","unstructured":"Greshock, J. et al. Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer Res. 67, 3594\u20133600 (2007).","journal-title":"Cancer Res."},{"key":"10650_CR72","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/labinvest.2011.72","volume":"91","author":"AB Mohseny","year":"2011","unstructured":"Mohseny, A. B. et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. 91, 1195\u20131205 (2011).","journal-title":"Lab. Invest."},{"key":"10650_CR73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/gcc.20717","volume":"49","author":"L Ottaviano","year":"2010","unstructured":"Ottaviano, L. et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49, 40\u201351 (2010).","journal-title":"Genes Chromosomes Cancer"},{"key":"10650_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2006.03.006","volume":"60","author":"ETH Ek","year":"2006","unstructured":"Ek, E. T. H., Dass, C. R. & Choong, P. F. M. Commonly used mouse models of osteosarcoma. Crit. Rev. Oncol. Hematol. 60, 1\u20138 (2006).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10650_CR75","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X","volume":"27","author":"RM McAllister","year":"1971","unstructured":"McAllister, R. M. et al. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27, 397\u2013402 (1971).","journal-title":"Cancer"},{"key":"10650_CR76","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/ijc.2910190411","volume":"19","author":"JS Rhim","year":"1977","unstructured":"Rhim, J. S., Putman, D. L., Arnstein, P., Huebner, R. J. & McAllister, R. M. Characterization of human cells transformed in vitro by N-methyl-N\u2019-nitro-N-nitrosoguanidine. Int. J. Cancer 19, 505\u2013510 (1977).","journal-title":"Int. J. Cancer"},{"key":"10650_CR77","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","volume":"59","author":"J Fogh","year":"1977","unstructured":"Fogh, J., Fogh, J. M. & Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59, 221\u2013226 (1977).","journal-title":"J. Natl. Cancer Inst."},{"key":"10650_CR78","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.bone.2005.02.010","volume":"36","author":"H Orimo","year":"2005","unstructured":"Orimo, H. & Shimada, T. Regulation of the human tissue-nonspecific alkaline phosphatase gene expression by all-trans-retinoic acid in SaOS-2 osteosarcoma cell line. Bone 36, 866\u2013876 (2005).","journal-title":"Bone"},{"key":"10650_CR79","first-page":"246","volume":"35","author":"H Heremans","year":"1978","unstructured":"Heremans, H., Billiau, A., Cassiman, J. J., Mulier, J. C. & de Somer, P. In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology 35, 246\u2013252 (1978).","journal-title":"Oncology"},{"key":"10650_CR80","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/8756-3282(94)90305-0","volume":"15","author":"J Clover","year":"1994","unstructured":"Clover, J. & Gowen, M. Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone 15, 585\u2013591 (1994).","journal-title":"Bone"},{"key":"10650_CR81","doi-asserted-by":"crossref","unstructured":"Munoz-Garcia, J. et al. In vitro three-dimensional cell cultures for bone sarcomas. J. Bone Oncol. 30, 100379 (2021).","DOI":"10.1016\/j.jbo.2021.100379"},{"key":"10650_CR82","doi-asserted-by":"crossref","unstructured":"Bassi, G. et al. Scaffold-based 3D cellular models mimicking the heterogeneity of osteosarcoma stem cell niche. Sci. Rep. 10, 22294 (2020).","DOI":"10.1038\/s41598-020-79448-y"},{"key":"10650_CR83","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/bjc.2013.549","volume":"109","author":"SU Lauvrak","year":"2013","unstructured":"Lauvrak, S. U. et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br. J. Cancer 109, 2228\u20132236 (2013).","journal-title":"Br. J. Cancer"},{"key":"10650_CR84","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/cancers16010164","volume":"16","author":"V Sandhu","year":"2023","unstructured":"Sandhu, V., Bakkalci, D., Wei, S. & Cheema, U. Enhanced biomimetics of three-dimensional osteosarcoma models: a scoping review. Cancers 16, 164 (2023).","journal-title":"Cancers"},{"key":"10650_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121881","volume":"291","author":"D Banerjee","year":"2022","unstructured":"Banerjee, D. et al. Strategies for 3D bioprinting of spheroids: a comprehensive review. Biomaterials 291, 121881 (2022).","journal-title":"Biomaterials"},{"key":"10650_CR86","doi-asserted-by":"crossref","unstructured":"Cui, X., Hartanto, Y. & Zhang, H. Advances in multicellular spheroids formation. J. R. Soc. Interface 14, 20160877 (2017).","DOI":"10.1098\/rsif.2016.0877"},{"key":"10650_CR87","doi-asserted-by":"crossref","unstructured":"Zanoni, M. et al. 3D tumor spheroid models for in vitro therapeutic screening: A systematic approach to enhance the biological relevance of data obtained. Sci. Rep. 6, 19103 (2016).","DOI":"10.1038\/srep19103"},{"key":"10650_CR88","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/bit.24399","volume":"109","author":"AY Hsiao","year":"2012","unstructured":"Hsiao, A. Y. et al. 384 hanging drop arrays give excellent Z-factors and allow versatile formation of co-culture spheroids. Biotechnol. Bioeng. 109, 1293\u20131304 (2012).","journal-title":"Biotechnol. Bioeng."},{"key":"10650_CR89","doi-asserted-by":"crossref","unstructured":"Costa, E. C., de Melo-Diogo, D., Moreira, A. F., Carvalho, M. P. & Correia, I. J. Spheroids formation on non-adhesive surfaces by liquid overlay technique: consideration and practical approaches. Biotechnol. J. 13, 1700417 (2018).","DOI":"10.1002\/biot.201700417"},{"key":"10650_CR90","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jbiotec.2014.09.005","volume":"189","author":"M Rimann","year":"2014","unstructured":"Rimann, M. et al. An in vitro osteosarcoma 3D microtissue model for drug development. J. Biotechnol. 189, 129\u2013135 (2014).","journal-title":"J. Biotechnol."},{"key":"10650_CR91","doi-asserted-by":"crossref","unstructured":"Belisario, D. C. et al. ABCA1\/ABCB1 ratio determines chemo- and immune-sensitivity in human osteosarcoma. Cells 9, 647 (2020).","DOI":"10.3390\/cells9030647"},{"key":"10650_CR92","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"10650_CR93","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","volume":"162","author":"FM Vallette","year":"2019","unstructured":"Vallette, F. M. et al. Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem. Pharmacol. 162, 169\u2013176 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"10650_CR94","doi-asserted-by":"crossref","unstructured":"De Angelis, M. L., Francescangeli, F., La Torre, F. & Zeuner, A. Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front. Oncol. 9, 626 (2019).","DOI":"10.3389\/fonc.2019.00626"},{"key":"10650_CR95","doi-asserted-by":"crossref","unstructured":"Barbato, L., Bocchetti, M., Di Biase, A. & Regad, T. Cancer stem cells and targeting strategies. Cells. 8, 926 (2019).","DOI":"10.3390\/cells8080926"},{"key":"10650_CR96","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/bit.27381","volume":"117","author":"S Ozturk","year":"2020","unstructured":"Ozturk, S., Gorgun, C., Gokalp, S., Vatansever, S. & Sendemir, A. Development and characterization of cancer stem cell-based tumoroids as an osteosarcoma model. Biotechnol. Bioeng. 117, 2527\u20132539 (2020).","journal-title":"Biotechnol. Bioeng."},{"key":"10650_CR97","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.2147\/OTT.S112566","volume":"9","author":"NH Baek","year":"2016","unstructured":"Baek, N. H., Seo, O. W., Kim, M. S., Hulme, J. & An, S. S. A. Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time. Onco. Targets Ther. 9, 7207\u20137218 (2016).","journal-title":"Onco. Targets Ther."},{"key":"10650_CR98","doi-asserted-by":"crossref","unstructured":"Freeman, F. E., Burdis, R., Mahon, O. R., Kelly, D. J. & Artzi, N. A spheroid model of early and late-stage osteosarcoma mimicking the divergent relationship between tumor elimination and bone regeneration. Adv. Healthc. Mater. 11, e2101296 (2022).","DOI":"10.1002\/adhm.202101296"},{"key":"10650_CR99","doi-asserted-by":"crossref","unstructured":"Clevers, H. Modeling development and disease with organoids. Cell. 165, 1586\u20131597 (2016).","DOI":"10.1016\/j.cell.2016.05.082"},{"key":"10650_CR100","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/nprot.2014.158","volume":"9","author":"MA Lancaster","year":"2014","unstructured":"Lancaster, M. A. & Knoblich, J. A. Generation of cerebral organoids from human pluripotent stem cells. Nat. Protoc. 9, 2329\u20132340 (2014).","journal-title":"Nat. Protoc."},{"key":"10650_CR101","doi-asserted-by":"crossref","unstructured":"Zhu, X., Zhang, B., He, Y. & Bao, J. Liver organoids: formation strategies and biomedical applications. Tissue Eng Regen Med. 18, 573\u2013585 (2021).","DOI":"10.1007\/s13770-021-00357-w"},{"key":"10650_CR102","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-020-2352-3","volume":"582","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. Hair-bearing human skin generated entirely from pluripotent stem cells. Nature 582, 399\u2013404 (2020).","journal-title":"Nature"},{"key":"10650_CR103","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41422-020-00453-x","volume":"31","author":"M Qu","year":"2021","unstructured":"Qu, M. et al. Establishment of intestinal organoid cultures modeling injury-associated epithelial regeneration. Cell Res 31, 259\u2013271 (2021).","journal-title":"Cell Res"},{"key":"10650_CR104","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724\u20131743 (2016).","journal-title":"Nat. Protoc."},{"key":"10650_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22031195","volume":"22","author":"G Bassi","year":"2021","unstructured":"Bassi, G., Grimaudo, M. A., Panseri, S. & Montesi, M. Advanced multi-dimensional cellular models as emerging reality to reproduce in vitro the human body complexity. Int. J. Mol. Sci. 22, 1\u201328 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"10650_CR106","doi-asserted-by":"crossref","unstructured":"Yan, H. H. N., Chan, A. S., Lai, F. P. L. & Leung, S. Y. Organoid cultures for cancer modeling. Cell Stem Cell. 30, 917\u2013937 (2023).","DOI":"10.1016\/j.stem.2023.05.012"},{"key":"10650_CR107","doi-asserted-by":"crossref","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer. 18, 407\u2013418 (2018).","DOI":"10.1038\/s41568-018-0007-6"},{"key":"10650_CR108","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/stem.2455","volume":"35","author":"I Lombaert","year":"2017","unstructured":"Lombaert, I., Movahednia, M. M., Adine, C. & Ferreira, J. N. Concise review: salivary gland regeneration: therapeutic approaches from stem cells to tissue organoids. Stem Cells 35, 97\u2013105 (2017).","journal-title":"Stem Cells"},{"key":"10650_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-020-01429-y","volume":"37","author":"A He","year":"2020","unstructured":"He, A. et al. Organoid culture system for patient-derived lung metastatic osteosarcoma. Med. Oncol. 37, 105 (2020).","journal-title":"Med. Oncol."},{"key":"10650_CR110","first-page":"278","volume":"3","author":"G Turnbull","year":"2018","unstructured":"Turnbull, G. et al. 3D bioactive composite scaffolds for bone tissue engineering. Bioact. Mater. 3, 278\u2013314 (2018).","journal-title":"Bioact. Mater."},{"key":"10650_CR111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.actbio.2019.07.011","volume":"96","author":"M Pavlou","year":"2019","unstructured":"Pavlou, M. et al. Osteomimetic matrix components alter cell migration and drug response in a 3D tumour-engineered osteosarcoma model. Acta Biomater. 96, 247\u2013257 (2019).","journal-title":"Acta Biomater."},{"key":"10650_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101766","volume":"32","author":"K Menshikh","year":"2025","unstructured":"Menshikh, K. et al. 3D-printed \u03b2-TCP scaffold as a bone-mimicking environment for an engineered model of osteosarcoma: in vitro properties and transcriptomic insights. Mater. Today Bio 32, 101766 (2025).","journal-title":"Mater. Today Bio"},{"key":"10650_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123267","volume":"320","author":"C Jaiswal","year":"2025","unstructured":"Jaiswal, C. et al. 3D bioprinted microfluidic- based osteosarcoma-on-a chip model as a physiomimetic pre-clinical drug testing platform for anti-cancer drugs. Biomaterials 320, 123267 (2025).","journal-title":"Biomaterials"},{"key":"10650_CR114","doi-asserted-by":"publisher","first-page":"10547","DOI":"10.1021\/acs.chemrev.9b00789","volume":"120","author":"C Mota","year":"2020","unstructured":"Mota, C., Camarero-Espinosa, S., Baker, M. B., Wieringa, P. & Moroni, L. Bioprinting: from tissue and organ development to in vitro models. Chem. Rev. 120, 10547\u201310607 (2020).","journal-title":"Chem. Rev."},{"key":"10650_CR115","doi-asserted-by":"crossref","unstructured":"Gu, Z., Fu, J., Lin, H. & He, Y. Development of 3D bioprinting: From printing methods to biomedical applications. Asian J. Pharm. Sci. 15, 529\u2013557 (2020).","DOI":"10.1016\/j.ajps.2019.11.003"},{"key":"10650_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-020-0752-0","volume":"19","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Organ-on-a-chip: recent breakthroughs and future prospects. Biomed. Eng. Online 19, 9 (2020).","journal-title":"Biomed. Eng. Online"},{"key":"10650_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3718","volume":"4","author":"A Albanese","year":"2013","unstructured":"Albanese, A., Lam, A. K., Sykes, E. A., Rocheleau, J. V. & Chan, W. C. W. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat. Commun. 4, 2718 (2013).","journal-title":"Nat. Commun."},{"key":"10650_CR118","doi-asserted-by":"crossref","unstructured":"Ahadian, S. et al. Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies. Adv. Healthc. Mater. 7, 1700506 (2018).","DOI":"10.1002\/adhm.201800734"},{"key":"10650_CR119","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1182\/blood-2023-180166","volume":"142","author":"M Guha","year":"2023","unstructured":"Guha, M. et al. Establishment of human bone marrow-on-chip as a preclinical model to evaluate drug-induced toxicities and myelofibrosis patient-specific pathophysiology. Blood 142, 5611\u20135611 (2023).","journal-title":"Blood"},{"key":"10650_CR120","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.stem.2024.11.003","volume":"31","author":"A Georgescu","year":"2024","unstructured":"Georgescu, A. et al. Self-organization of the hematopoietic vascular niche and emergent innate immunity on a chip. Cell Stem Cell 31, 1847\u20131864.e6 (2024).","journal-title":"Cell Stem Cell"},{"key":"10650_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121245","volume":"280","author":"DE Glaser","year":"2022","unstructured":"Glaser, D. E. et al. Organ-on-a-chip model of vascularized human bone marrow niches. Biomaterials 280, 121245 (2022).","journal-title":"Biomaterials"},{"key":"10650_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120683","volume":"270","author":"MR Nelson","year":"2021","unstructured":"Nelson, M. R. et al. A multi-niche microvascularized human bone marrow (hBM) on-a-chip elucidates key roles of the endosteal niche in hBM physiology. Biomaterials 270, 120683 (2021).","journal-title":"Biomaterials"},{"key":"10650_CR123","doi-asserted-by":"crossref","unstructured":"Erbay, I. H. et al. Bioengineering bone-on-a-chip model harnessing osteoblastic and osteoclastic resolution. Adv. Eng. Mater. 25, 2201063 (2023).","DOI":"10.1002\/adem.202201063"},{"key":"10650_CR124","doi-asserted-by":"crossref","unstructured":"Galv\u00e1n-Chac\u00f3n, V. P. et al. Bone-on-a-chip: a microscale 3D biomimetic model to study bone regeneration. Adv. Eng. Mater. 24, 2101467 (2022).","DOI":"10.1002\/adem.202101467"},{"key":"10650_CR125","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.addr.2019.04.003","volume":"140","author":"A Chramiec","year":"2019","unstructured":"Chramiec, A. & Vunjak-Novakovic, G. Tissue engineered models of healthy and malignant human bone marrow. Adv. Drug Deliv. Rev. 140, 78\u201392 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10650_CR126","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41551-019-0495-z","volume":"4","author":"DB Chou","year":"2020","unstructured":"Chou, D. B. et al. On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. Nat. Biomed. Eng. 4, 394\u2013406 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"10650_CR127","first-page":"1","volume":"34","author":"Z Lu","year":"2024","unstructured":"Lu, Z. et al. An osteosarcoma-on-a-chip model for studying osteosarcoma matrix-cell interactions and drug responses. Bioact. Mater. 34, 1\u201316 (2024).","journal-title":"Bioact. Mater."},{"key":"10650_CR128","doi-asserted-by":"publisher","first-page":"045025","DOI":"10.1088\/1758-5090\/ad6cf9","volume":"16","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. Bone-on-a-chip simulating bone metastasis in osteoporosis. Biofabrication 16, 045025 (2024).","journal-title":"Biofabrication"},{"key":"10650_CR129","doi-asserted-by":"crossref","unstructured":"Bekisz, S. & Geris, L. Cancer modeling: From mechanistic to data-driven approaches, and from fundamental insights to clinical applications. J. Comput. Sci. 46, 101198 (2020).","DOI":"10.1016\/j.jocs.2020.101198"},{"key":"10650_CR130","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1007\/s11831-021-09554-1","volume":"28","author":"S Anvari","year":"2021","unstructured":"Anvari, S., Nambiar, S., Pang, J. & Maftoon, N. Computational models and simulations of cancer metastasis. Arch. Comput. Methods Eng. 28, 4837\u20134859 (2021).","journal-title":"Arch. Comput. Methods Eng."},{"key":"10650_CR131","first-page":"828701","volume":"2012","author":"Trisilowati","year":"2012","unstructured":"Trisilowati & Mallet, D. G. In silico experimental modeling of cancer treatment. ISRN Oncol. 2012, 828701 (2012).","journal-title":"ISRN Oncol."},{"key":"10650_CR132","doi-asserted-by":"publisher","first-page":"599","DOI":"10.18632\/oncoscience.85","volume":"1","author":"PC Sanchez-Diaz","year":"2014","unstructured":"Sanchez-Diaz, P. C. et al. In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. Oncoscience 1, 599\u2013608 (2014).","journal-title":"Oncoscience"},{"key":"10650_CR133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10441-025-09494-4","volume":"73","author":"MI Romero Rodr\u00edguez","year":"2025","unstructured":"Romero Rodr\u00edguez, M. I., Vargas Pino, J. C. & Sierra-Ball\u00e9n, E. L. Tumor growth, proliferation and diffusion in osteosarcoma. Acta. Biotheoret. 73, 4 (2025).","journal-title":"Acta. Biotheoret."},{"key":"10650_CR134","doi-asserted-by":"publisher","first-page":"12976","DOI":"10.1038\/s41598-020-69862-7","volume":"10","author":"M Cortesi","year":"2020","unstructured":"Cortesi, M., Liverani, C., Mercatali, L., Ibrahim, T. & Giordano, E. An in-silico study of cancer cell survival and spatial distribution within a 3D microenvironment. Sci. Rep. 10, 12976 (2020).","journal-title":"Sci. Rep."},{"key":"10650_CR135","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/cancers15102750","volume":"15","author":"M Nikfar","year":"2023","unstructured":"Nikfar, M., Mi, H., Gong, C., Kimko, H. & Popel, A. S. Quantifying intratumoral heterogeneity and immunoarchitecture generated in-silico by a spatial quantitative systems pharmacology model. Cancers 15, 2750 (2023).","journal-title":"Cancers"},{"key":"10650_CR136","doi-asserted-by":"crossref","unstructured":"Jinnah, A. H., Zacks, B. C., Gwam, C. U. & Kerr, B. A. Emerging and established models of bone metastasis. Cancers (Basel). 10, 176 (2018).","DOI":"10.3390\/cancers10060176"},{"key":"10650_CR137","doi-asserted-by":"crossref","unstructured":"Gallaher, J. et al. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin. Exper. Metastasis. 31, 991\u2013999 (2014).","DOI":"10.1007\/s10585-014-9674-1"},{"key":"10650_CR138","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1142\/S0218202502001878","volume":"12","author":"D Ambrosi","year":"2002","unstructured":"Ambrosi, D. & Preziosi, L. On the closure of mass balance models for tumor growth. Math. Models Methods Appl. Sci. 12, 737\u2013754 (2002).","journal-title":"Math. Models Methods Appl. Sci."},{"key":"10650_CR139","doi-asserted-by":"publisher","unstructured":"Anderson, A. R. A., Chaplain, M. A. J. & McDougall, S. A hybrid discrete-continuum model of tumour-induced angiogenesis. In: Modeling Tumor Vasculature 105\u2013133 (Springer New York, New York, 2012). https:\/\/doi.org\/10.1007\/978-1-4614-0052-3_5.","DOI":"10.1007\/978-1-4614-0052-3_5"},{"key":"10650_CR140","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1158\/0008-5472.CAN-08-3834","volume":"69","author":"EL Bearer","year":"2009","unstructured":"Bearer, E. L. et al. Multiparameter computational modeling of tumor invasion. Cancer Res. 69, 4493\u20134501 (2009).","journal-title":"Cancer Res."},{"key":"10650_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1137\/050629215","volume":"5","author":"BP Ayati","year":"2006","unstructured":"Ayati, B. P., Webb, G. F. & Anderson, A. R. A. Computational methods and results for structured multiscale models of tumor invasion. Multiscale Modeling Simul. 5, 1\u201320 (2006).","journal-title":"Multiscale Modeling Simul."},{"key":"10650_CR142","doi-asserted-by":"crossref","unstructured":"Bresch, D., Colin, T., Grenier, E., Ribba, B. & Saut, O. Computational modeling of solid tumor growth: the avascular stage. SIAM J. Sci. Comput. 32, 2321\u20132344 (2010).","DOI":"10.1137\/070708895"},{"key":"10650_CR143","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-13-2652","volume":"74","author":"A Araujo","year":"2014","unstructured":"Araujo, A., Cook, L. M., Lynch, C. C. & Basanta, D. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Cancer Res. 74, 2391\u20132401 (2014).","journal-title":"Cancer Res."},{"key":"10650_CR144","doi-asserted-by":"crossref","unstructured":"Hu, Y., Mohammad Mirzaei, N. & Shahriyari, L. Bio-mechanical model of osteosarcoma tumor microenvironment: a porous media approach. Cancers. 14, 6143 (2022).","DOI":"10.3390\/cancers14246143"},{"key":"10650_CR145","doi-asserted-by":"publisher","first-page":"eaax0938","DOI":"10.1126\/sciadv.aax0938","volume":"6","author":"Y Kameo","year":"2020","unstructured":"Kameo, Y., Miya, Y., Hayashi, M., Nakashima, T. & Adachi, T. In silico experiments of bone remodeling explore metabolic diseases and their drug treatment. Sci. Adv. 6, eaax0938 (2020).","journal-title":"Sci. Adv."},{"key":"10650_CR146","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s10237-017-0939-x","volume":"16","author":"CC Villette","year":"2017","unstructured":"Villette, C. C. & Phillips, A. T. M. Microscale poroelastic metamodel for efficient mesoscale bone remodelling simulations. Biomech. Model. Mechanobiol. 16, 2077\u20132091 (2017).","journal-title":"Biomech. Model. Mechanobiol."},{"key":"10650_CR147","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1089\/ten.tea.2010.0130","volume":"16","author":"L Geris","year":"2010","unstructured":"Geris, L. et al. Mechanical loading affects angiogenesis and osteogenesis in an in vivo bone Chamber: a modeling study. Tissue Eng. Part A 16, 3353\u20133361 (2010).","journal-title":"Tissue Eng. Part A"},{"key":"10650_CR148","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/23335432.2015.1017609","volume":"2","author":"ATM Phillips","year":"2015","unstructured":"Phillips, A. T. M., Villette, C. C. & Modenese, L. Femoral bone mesoscale structural architecture prediction using musculoskeletal and finite element modelling. Int. Biomech. 2, 43\u201361 (2015).","journal-title":"Int. Biomech."},{"key":"10650_CR149","doi-asserted-by":"crossref","unstructured":"Urdeitx, P., Mousavi, S. J., Avril, S. & Doweidar, M. H. Computational modeling of multiple myeloma interactions with resident bone marrow cells. Comput. Biol. Med. 153, 106458 (2023).","DOI":"10.1016\/j.compbiomed.2022.106458"},{"key":"10650_CR150","doi-asserted-by":"crossref","unstructured":"Stadelmann, M. A. et al. Conventional finite element models estimate the strength of metastatic human vertebrae despite alterations of the bone\u2019s tissue and structure. Bone 141, 115598 (2020).","DOI":"10.1016\/j.bone.2020.115598"},{"key":"10650_CR151","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1158\/0008-5472.CAN-18-1804","volume":"79","author":"X Lai","year":"2019","unstructured":"Lai, X. et al. Toward personalized computer simulation of breast cancer treatment: a multiscale pharmacokinetic and pharmacodynamic model informed by multitype patient data. Cancer Res. 79, 4293\u20134304 (2019).","journal-title":"Cancer Res"},{"key":"10650_CR152","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, Z., Zhang, B. & Yang, F. Comprehensive diagnostic model for osteosarcoma classification using CT imaging features. J. Bone Oncol. 47, 100622 (2024).","DOI":"10.1016\/j.jbo.2024.100622"},{"key":"10650_CR153","doi-asserted-by":"crossref","unstructured":"Borji, A., Kronreif, G., Angermayr, B. & Hatamikia, S. Advanced hybrid deep learning model for enhanced evaluation of osteosarcoma histopathology images. Front. Med. 12, 1555907 (2025).","DOI":"10.3389\/fmed.2025.1555907"},{"key":"10650_CR154","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.21873\/anticanres.15937","volume":"42","author":"S Consalvo","year":"2022","unstructured":"Consalvo, S. et al. Two-phase deep learning algorithm for detection and differentiation of Ewing sarcoma and acute osteomyelitis in paediatric radiographs. Anticancer Res. 42, 4371\u20134380 (2022).","journal-title":"Anticancer Res."},{"key":"10650_CR155","doi-asserted-by":"crossref","unstructured":"Zhao, Q. et al. Feasibility of machine learning\u2013based modeling and prediction to assess osteosarcoma outcomes. Sci. Rep. 15, 17386 (2025).","DOI":"10.1038\/s41598-025-00179-z"},{"key":"10650_CR156","doi-asserted-by":"crossref","unstructured":"Zhou, X. & Liu, J. A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways. BMC Cancer 14, 618 (2014).","DOI":"10.1186\/1471-2407-14-618"},{"key":"10650_CR157","doi-asserted-by":"publisher","unstructured":"Villette, C. C. et al. Semi-mechanistic efficacy model for PARP + ATR inhibitors\u2014application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs: translational therapeutics. Br. J. Cancer https:\/\/doi.org\/10.1038\/s41416-024-02935-w (2025).","DOI":"10.1038\/s41416-024-02935-w"},{"key":"10650_CR158","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/cncr.20152","volume":"100","author":"KR Crews","year":"2004","unstructured":"Crews, K. R. et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100, 1724\u20131733 (2004).","journal-title":"Cancer"},{"key":"10650_CR159","doi-asserted-by":"crossref","unstructured":"Le, T., Su, S., Kirshtein, A. & Shahriyari, L. Data-driven mathematical model of osteosarcoma. Cancers. 13, 2367 (2021).","DOI":"10.3390\/cancers13102367"},{"key":"10650_CR160","doi-asserted-by":"crossref","unstructured":"Le, T., Su, S. & Shahriyari, L. Investigating optimal chemotherapy options for osteosarcoma patients through a mathematical model. Cells 10, 2009 (2021).","DOI":"10.3390\/cells10082009"},{"key":"10650_CR161","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12885-018-4302-0","volume":"18","author":"C Jean-Quartier","year":"2018","unstructured":"Jean-Quartier, C., Jeanquartier, F., Jurisica, I. & Holzinger, A. In silico cancer research towards 3R. BMC Cancer 18, 408 (2018).","journal-title":"BMC Cancer"},{"key":"10650_CR162","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/pharmaceutics13050704","volume":"13","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. The combination of cell-cultured technology and in silico model to inform drug development. Pharmaceutics 13, 704 (2021).","journal-title":"Pharmaceutics"},{"key":"10650_CR163","first-page":"79","volume":"42","author":"GM Ramzy","year":"2023","unstructured":"Ramzy, G. M. et al. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma. J. Exp. Clin. Cancer Res. 2023 42:1 42, 79\u201379 (2023).","journal-title":"J. Exp. Clin. Cancer Res. 2023 42:1"},{"key":"10650_CR164","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.mehy.2015.06.015","volume":"85","author":"KA Rejniak","year":"2015","unstructured":"Rejniak, K. A., Lloyd, M. C., Reed, D. R. & Bui, M. M. Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials. Med. Hypotheses 85, 348\u2013354 (2015).","journal-title":"Med. Hypotheses"},{"key":"10650_CR165","doi-asserted-by":"crossref","unstructured":"Musuamba, F. T. et al. Verifying and validating quantitative systems pharmacology and in silico models in drug development: current needs, gaps, and challenges. CPT: Pharmacometrics and Systems Pharmacology vol. 9 195\u2013197 (2020).","DOI":"10.1002\/psp4.12504"},{"key":"10650_CR166","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/jcp.22766","volume":"227","author":"Y Kam","year":"2012","unstructured":"Kam, Y., Rejniak, K. A. & Anderson, A. R. A. Cellular modeling of cancer invasion: Integration of in silico and in vitro approaches. J. Cell. Physiol. 227, 431 (2012).","journal-title":"J. Cell. Physiol."},{"key":"10650_CR167","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41524-020-00366-8","volume":"6","author":"NR Stillman","year":"2020","unstructured":"Stillman, N. R., Kovacevic, M., Balaz, I. & Hauert, S. In silico modelling of cancer nanomedicine, across scales and transport barriers. npj Comput. Mater. 2020 6:1 6, 92 (2020).","journal-title":"npj Comput. Mater. 2020 6:1"},{"key":"10650_CR168","unstructured":"EU-Stands 4 pm: Home. https:\/\/www.eu-stands4pm.eu\/."},{"key":"10650_CR169","unstructured":"European Virtual Human Twin. https:\/\/www.edith-csa.eu\/."},{"key":"10650_CR170","doi-asserted-by":"crossref","unstructured":"Brunak, S. et al. Towards standardization guidelines for in silico approaches in personalized medicine. J. Integr. Bioinform. 17, 20200006 (2020).","DOI":"10.1515\/jib-2020-0006"},{"key":"10650_CR171","doi-asserted-by":"crossref","unstructured":"Viceconti, Marco. & Emili, Luca. Toward good simulation practice: best practices for the use of computational modelling and simulation in the regulatory process of biomedical products. 144 (Springer Nature, 2024).","DOI":"10.1007\/978-3-031-48284-7"},{"key":"10650_CR172","doi-asserted-by":"publisher","unstructured":"Bassi, G. et al. 3D Tumor-engineered model replicating the osteosarcoma stem cell niche and in vivo tumor complexity. ACS Appl. Mater. Interfaces https:\/\/doi.org\/10.1021\/acsami.4c02567 (2024).","DOI":"10.1021\/acsami.4c02567"},{"key":"10650_CR173","doi-asserted-by":"crossref","unstructured":"Brancato, V., Oliveira, J. M., Correlo, V. M., Reis, R. L. & Kundu, S. C. Could 3D models of cancer enhance drug screening? Biomaterials. 232, 119744 (2020).","DOI":"10.1016\/j.biomaterials.2019.119744"},{"key":"10650_CR174","doi-asserted-by":"crossref","unstructured":"Colella, G. et al. Sarcoma spheroids and organoids\u2014 Promising tools in the era of personalized medicine. Int. J. Mol. Sci. 19, 615 (2018).","DOI":"10.3390\/ijms19020615"},{"key":"10650_CR175","doi-asserted-by":"crossref","unstructured":"Grimes, D. R., Fletcher, A. G. & Partridge, M. Oxygen consumption dynamics in steady-state tumour models. R. Soc. Open Sci. 1, 140080 (2014).","DOI":"10.1098\/rsos.140080"},{"key":"10650_CR176","doi-asserted-by":"crossref","unstructured":"Guerrieri, A. N. et al. Innovative options for bone metastasis treatment: an extensive analysis on biomaterials-based strategies for orthopedic surgeons. Front. Bioeng. Biotechnol. 8, 589964 (2020).","DOI":"10.3389\/fbioe.2020.589964"},{"key":"10650_CR177","doi-asserted-by":"crossref","unstructured":"Komez, A. et al. A two-compartment bone tumor model to investigate interactions between healthy and tumor cells. Biomed. Mater. 15, 035007 (2020).","DOI":"10.1088\/1748-605X\/ab6b31"},{"key":"10650_CR178","doi-asserted-by":"crossref","unstructured":"Laschke, M. W. & Menger, M. D. Life is 3D: Boosting spheroid function for tissue engineering. Trends Biotechnol. 35, 133\u2013144 (2017).","DOI":"10.1016\/j.tibtech.2016.08.004"},{"key":"10650_CR179","doi-asserted-by":"crossref","unstructured":"Ricci, C., Moroni, L. & Danti, S. Cancer tissue engineering\u2014new perspectives in understanding the biology of solid tumours\u2014a critical review. OA Tissue Eng. 1, 1\u20137 (2013).","DOI":"10.13172\/2052-9643-1-1-607"},{"key":"10650_CR180","doi-asserted-by":"crossref","unstructured":"Yu, F., Hunziker, W., & Choudhury, D. Engineering microfluidic organoid-on-a-chip platforms. Micromachines. 10, 165 (2019).","DOI":"10.3390\/mi10030165"},{"key":"10650_CR181","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/biology10020135","volume":"10","author":"P Urdeitx","year":"2021","unstructured":"Urdeitx, P. & Doweidar, M. H. Enhanced piezoelectric fibered extracellular matrix to promote cardiomyocyte maturation and tissue formation: a 3D computational model. Biology 10, 135 (2021).","journal-title":"Biology"},{"key":"10650_CR182","doi-asserted-by":"crossref","unstructured":"Sellers, G. S. et al. From conventional to cutting edge: an exploration of osteosarcoma treatments. Med. Oncol. 42, 81 (2025).","DOI":"10.1007\/s12032-025-02629-0"},{"key":"10650_CR183","doi-asserted-by":"crossref","unstructured":"Ottesen, T. D. et al. Characteristics, management, and outcomes of patients with osteosarcoma: an analysis of outcomes from the national cancer database. J. Am. Acad. Orthop. Surg. Glob. Res. Rev. 6, e22.00009 (2022).","DOI":"10.5435\/JAAOSGlobal-D-22-00009"},{"key":"10650_CR184","doi-asserted-by":"crossref","unstructured":"Papakonstantinou, E. et al. Prognostic factors in high-grade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis. Cancer Epidemiol. 90, 102551 (2024).","DOI":"10.1016\/j.canep.2024.102551"},{"key":"10650_CR185","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28352","volume":"68","author":"BR Eaton","year":"2021","unstructured":"Eaton, B. R. et al. Osteosarcoma. Pediatr. Blood Cancer 68, e28352 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"10650_CR186","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/cancers13030388","volume":"13","author":"MJ Brookes","year":"2021","unstructured":"Brookes, M. J. et al. Surgical advances in osteosarcoma. Cancers 13, 388 (2021).","journal-title":"Cancers"},{"key":"10650_CR187","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/os.12702","volume":"12","author":"M Xu","year":"2020","unstructured":"Xu, M., Wang, Z., Yu, X. C., Lin, J. H. & Hu, Y. C. Guideline for Limb-Salvage Treatment of Osteosarcoma. Orthop. Surg. 12, 1021\u20131029 (2020).","journal-title":"Orthop. Surg."},{"key":"10650_CR188","unstructured":"Localized Osteosarcoma - Virginia Cancer Institute. https:\/\/www.vacancer.com\/cancer\/bone-cancer\/osteosarcoma-overview\/localized-osteosarcoma\/."},{"key":"10650_CR189","doi-asserted-by":"crossref","unstructured":"Zhang, B. et al. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis. J Orthop Surg Res. 15, 51 (2020).","DOI":"10.1186\/s13018-020-1576-0"},{"key":"10650_CR190","doi-asserted-by":"crossref","unstructured":"Argenziano, M. et al. Osteosarcoma in children: not only chemotherapy. Pharmaceuticals (Basel). 14, 923 (2021).","DOI":"10.3390\/ph14090923"},{"key":"10650_CR191","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","volume":"9","author":"LC Sayles","year":"2019","unstructured":"Sayles, L. C. et al. Genome-informed targeted therapy for osteosarcoma. Cancer Discov. 9, 46\u201363 (2019).","journal-title":"Cancer Discov."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10650-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10650-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10650-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:01:52Z","timestamp":1784131312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10650-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":191,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10650"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10650-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"966"}}